<DOC>
	<DOC>NCT01036932</DOC>
	<brief_summary>The purpose of the study is to determine whether Granulocyte Colony Stimulating factor(G-CSF) therapy is effective in the treatment of patients with Acute on chronic liver failure(ACLF). The investigators hypothesize that ACLF is a disease where severe hepatic impairment is accompanied by impaired hepatic regeneration. BMC mobilization using G-CSF therapy, or G-CSF therapy per se would increase the regenerative capacity of the liver and shall lead to clinical, biochemical and histological improvements in patients with ACLF.</brief_summary>
	<brief_title>Granulocyte Colony Stimulating Factor(G-CSF) Therapy for Patients With ACLF</brief_title>
	<detailed_description />
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Patients with acute hepatic insult manifesting as jaundice (Sr. Bil. ≥5 mg/dL) and coagulopathy (INR≥1.5), complicated within 4 weeks by ascites and/or encephalopathy in a patient with previously diagnosed or undiagnosed chronic liver disease.(APASL criteria) HCC or portal vein thrombosis. Refusal to participate in the study. Sepsis ( Any culture positive: blood, urine, focus of infection on Xray chest, any other obvious source of infection: UTI, SBP) Multi organ failure. Grade 3 or 4 hepatic encephalopathy.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>